This discrepancy may be due to the fact that the renal effect of exenatide in healthy men may differ from that in insulin-resistant subjects and T2DM patients, which could explain the above-mentioned decrease in GFR after GLP-1 peptide infusion in these individuals. Here, GLP1R is linked to type 2 diabetes mellitus.